These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22491982)

  • 1. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
    Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
    Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
    Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
    Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
    Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
    Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
    Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
    World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
    Nozawa M; Inagaki T; Nagao K; Nishioka T; Komura T; Esa A; Kitagawa M; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uejima S; Matsuyama H; Hara I; Uemura H
    Int J Clin Oncol; 2014 Aug; 19(4):693-701. PubMed ID: 23912936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
    Kashiwabara T; Suda S
    BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate].
    Nishizawa S; Yamauchi T; Sawada Y
    Hinyokika Kiyo; 2007 Dec; 53(12):891-5. PubMed ID: 18203529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
    Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
    J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
    Facchini G; Caraglia M; Morabito A; Marra M; Piccirillo MC; Bochicchio AM; Striano S; Marra L; Nasti G; Ferrari E; Leopardo D; Vitale G; Gentilini D; Tortoriello A; Catalano A; Budillon A; Perrone F; Iaffaioli RV
    Cancer Biol Ther; 2010 Sep; 10(6):543-8. PubMed ID: 20657175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
    Yasuda Y; Fujii Y; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
    Int J Clin Oncol; 2013 Oct; 18(5):877-83. PubMed ID: 22965827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R; Sharma N; Gupta NP
    Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report.
    Samelis GF; Ekmektzoglou KA; Tsiakou A; Giannakaki S; Georgoulias D; Christophilopoulos K
    J BUON; 2011; 16(4):738-43. PubMed ID: 22331731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.